Your AI-Trained Oncology Knowledge Connection!
Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.
Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.
Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.
Richard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.
Bruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.
Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.
Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.
While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.
As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.
Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.
Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.
Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.
Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.
Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.
Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.
Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.
Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.
Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.
Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.
Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.
Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.
Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.
Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.
Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.
The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.
David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.
Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.
Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.
Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.
